CCM
JNP

Cadence Capital Management’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Cadence Capital Management’s Portfolio JNP Stock Details JNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-127,598
Closed -$894K – 674
2016
Q2 		$894K Buy
127,598
+13,066
+11% +$92.1K 0.07% 315
2016
Q1 		$757K Buy
114,532
+32,140
+39% +$237K 0.05% 377
2015
Q4 		$849K Sell
82,392
-5,840
-7% -$67.7K 0.06% 345
2015
Q3 		$1.04M Sell
88,232
-63,664
-42% -$704K 0.07% 287
2015
Q2 		$1.39M Buy
+151,896
New +$1.15M 0.08% 313

Other funds holding JNP

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Cadence Capital Management's JNP Position: Q3 2016 in Review

Cadence Capital Management sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2016, closing a stake of 127,598 shares — an estimated $894K sold.

Cadence Capital Management first reported a position in JNP in Q2 2015 and held it in 5 quarters. The position peaked at $1.39M in Q2 2015. 46 funds tracked by Wall St. Rank hold JNP as of Q3 2016.

  • Cadence Capital Management reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Cadence Capital Management sold 127,598 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2016, an estimated $894K.
  • Cadence Capital Management first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q2 2015 and held it in 5 quarters.
  • Cadence Capital Management's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $1.39M in Q2 2015.
  • 46 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2016.

Based on Cadence Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.